Literature DB >> 15814119

Premalignant and early squamous cell carcinoma.

Anjali K Butani1, Anjali Butani, David M Arbesfeld, Robert A Schwartz.   

Abstract

Actinic keratosis (AK) is a common sun-induced precancerous neoplasm confined to the epidermis. The AK is the initial manifestation of a continuum of clinical and histologic abnormalities that progresses to invasive squamous cell carcinoma (SCC). Bowen's disease, also known as squamous cell carcinoma in situ, represents early SCC confined to the epidermis. More than half of all SCCs contain p53 tumor suppressor gene mutations. Like SCCs, the vast majority of AKs and Bowen's disease lesions are asymptomatic. Each AK and suspicious lesion should be treated before it progresses to invasive SCC. Destructive modalities, such as cryosurgery using liquid nitrogen and electrodesiccation and curettage, usually performed by a dermatologist, are the mainstays of therapy.

Entities:  

Mesh:

Year:  2005        PMID: 15814119     DOI: 10.1016/j.cps.2004.11.001

Source DB:  PubMed          Journal:  Clin Plast Surg        ISSN: 0094-1298            Impact factor:   2.017


  4 in total

1.  Age-associated inflammation connects RAS-induced senescence to stem cell dysfunction and epidermal malignancy.

Authors:  L Golomb; A Sagiv; I S Pateras; A Maly; V Krizhanovsky; V G Gorgoulis; M Oren; A Ben-Yehuda
Journal:  Cell Death Differ       Date:  2015-03-20       Impact factor: 15.828

2.  Photodynamic therapy in combination with CO2 laser for the treatment of Bowen's disease.

Authors:  Hong Cai; Yi-xia Wang; Ji-Chun Zheng; Ping Sun; Zhi-yong Yang; Yuan-li Li; Xiao-yong Liu; Qiang Li; Wei Liu
Journal:  Lasers Med Sci       Date:  2015-04-22       Impact factor: 3.161

Review 3.  How to treat actinic keratosis? An update.

Authors:  Claudia Costa; Massimiliano Scalvenzi; Fabio Ayala; Gabriella Fabbrocini; Giuseppe Monfrecola
Journal:  J Dermatol Case Rep       Date:  2015-06-30

4.  Clinicopathological study of 21 cases of eyelid actinic keratosis.

Authors:  Elena López-Tizón; Enrique Mencía-Gutiérrez; María Garrido-Ruíz; Esperanza Gutiérrez-Díaz; Fernando López-Ríos
Journal:  Int Ophthalmol       Date:  2008-07-17       Impact factor: 2.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.